1887

oa SA Pharmaceutical Journal - Januvia®: sitagliptin for type 2 diabetes : drug info : new product focus

 

Abstract

Sitagliptin monotherapy, or as add-on therapy, is generally well tolerated with the additional benefit of causing weight loss in patients with type 2 diabetes. Sitagliptin also has a lower potential for hypoglycaemic events because of the glucose-dependent mechanism of action.

Loading

Article metrics loading...

/content/mp_sapj/80/1/EJC131713
2013-01-01
2016-12-06
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error